Ginkgo Results Presentation Deck
Diversity in downstream value structures, some being realized today
Milestones
Lump-sum payment upon the achievement of
specified criteria
Case studies generating value today:
1
CRONOS
GROUP
Ginkgo may unlock over
$100M of milestones upon
program completion and
commercialization of all
programs(1)
Examples of other active programs:
Biogen
Up to $115M in milestone
payments
Royalties
Royalties based on sales of end products
(structures can vary: percent of revenue, cost
of goods sold, etc.)
Caldevron
Roche
Note: Illustrative economics; variation exists between programs
(1) Value granted upon commercialization and achievement of technical milestones; actual value of shares depends on share price.
Tiered royalty on sales
based on efficiency of
process; high end far
exceeds typical rates in
biopharma industry
Tiered royalties up to
double digits on sales
3
Equity
Equity grants in new companies + benefit
from appreciation driven by successful
programs
motif
FOODWORKS
JOYN
BIO
Ginkgo received Series A
shares ($90M strategic
round); value appreciated
during Series B funding
($226M raised)
Ginkgo owns approx.
35% of joint-venture
with Bayer
H1 UPDATE | AUGUST 2021
GINKGO BIOWORKS
16View entire presentation